FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christopher Surratt

Research Profile

Chemicals & Drugs

Anatomy

COS Cells

Concepts & Ideas

Physiology

Living Beings

Rats
Faculty

Co-author Network

Publications

TOP 3
Sankar Manepalli; Jeffry D Madura; Christopher K Surratt; Tammy L Nolan
Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.
Sankar Manepalli; Christopher K Surratt; Laura M Geffert; Jeffry D Madura
Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.
Christopher K Surratt; Khalid M Kamal; Peter L D Wildfong
Research funding expectations as a function of faculty teaching/administrative workload.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christopher Surratt (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sankar Manepalli; Jeffry D Madura; Christopher K Surratt; Tammy L Nolan
Monoamine transporter structure, function, dynamics, and drug discovery: a computational perspective.
The AAPS journal 2012;14(4):820-31.
2011: Sankar Manepalli; Christopher K Surratt; Laura M Geffert; Jeffry D Madura
Discovery of novel selective serotonin reuptake inhibitors through development of a protein-based pharmacophore.
Journal of chemical information and modeling 2011;51(9):2417-26.
2011: Christopher K Surratt; Khalid M Kamal; Peter L D Wildfong
Research funding expectations as a function of faculty teaching/administrative workload.
Research in social & administrative pharmacy : RSAP 2011;7(2):192-201.
2011: David J Lapinsky; Ranganadh Velagaleti; Nageswari Yarravarapu; Yi Liu; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Rejwi Acharya; Roxanne A Vaughan; Howard M Deutsch
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.
Bioorganic & medicinal chemistry 2011;19(1):504-12.
2010: Theresa A Kopajtic; Yi Liu; Christopher K Surratt; David M Donovan; Amy Hauck Newman; Jonathan L Katz
Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability.
The Journal of pharmacology and experimental therapeutics 2010;335(3):703-14.
2010: Patrick C Gedeon; Martín Indarte; Christopher K Surratt; Jeffry D Madura
Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer.
Proteins 2010;78(4):797-811.
2009: David J Lapinsky; Shaili Aggarwal; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Roxanne A Vaughan
A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.
Bioorganic & medicinal chemistry 2009;17(11):3770-4.
2008: Martín Indarte; Jeffry D Madura; Christopher K Surratt
Dopamine transporter comparative molecular modeling and binding site prediction using the LeuT(Aa) leucine transporter as a template.
Proteins 2008;70(3):1033-46.
2007: Christopher K Surratt; Shane P Desselle
Pharmacy students' perceptions of a teaching evaluation process.
American journal of pharmaceutical education 2007;71(1):6.
2007: Okechukwu T Ukairo; Suneetha Ramanujapuram; Christopher K Surratt
Fluctuation of the dopamine uptake inhibition potency of cocaine, but not amphetamine, at mammalian cells expressing the dopamine transporter.
Brain research 2007;1131(1):68-76.
2006: Christopher K Surratt
Creation of a graduate oral/written communication skills course.
American journal of pharmaceutical education 2006;70(1):5.
2006: Christopher K Surratt; Paula Witt-Enderby; David A Johnson; Carl A Anderson; J Douglas Bricker; Vicki L Davis; Steven M Firestine; Wilson S Meng
Development of a neuroscience-oriented "methods" course for graduate students of pharmacology and toxicology.
CBE life sciences education 2006;5(2):188-96.
2005: Okechukwu T Ukairo; Corry D Bondi; Amy Hauck Newman; Santosh S Kulkarni; Alan P Kozikowski; Stephen Pan; Christopher K Surratt
Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue.
The Journal of pharmacology and experimental therapeutics 2005;314(2):575-83.
2005: Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.
The AAPS journal 2005;7(3):E739-51.
2005: Christopher K Surratt; Wendy R Adams
G protein-coupled receptor structural motifs: relevance to the opioid receptors.
Current topics in medicinal chemistry 2005;5(3):315-24.
2003: Wenfei Wang; Mark S Sonders; Okechukwu T Ukairo; Helen Scott; Megan K Kloetzel; Christopher K Surratt
Dissociation of high-affinity cocaine analog binding and dopamine uptake inhibition at the dopamine transporter.
Molecular pharmacology 2003;64(2):430-9.
2003: Charles E Spivak; Carol L Beglan; Christian Zöllner; Christopher K Surratt
beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.
Synapse (New York, N.Y.) 2003;49(1):55-60.
2000: Christian Zöllner; P S Johnson; J Bei Wang; A J Roy; K M Layton; J Min Wu; Christopher K Surratt
Control of mu opioid receptor expression by modification of cDNA 5'- and 3'-noncoding regions.
Brain research. Molecular brain research 2000;79(1-2):159-62.
1999: P Zhang; P S Johnson; Christian Zöllner; W Wang; Zaijie Jim Wang; A E Montes; B K Seidleck; C J Blaschak; Christopher K Surratt
Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane.
Brain research. Molecular brain research 1999;72(2):195-204.
1997: Charles E Spivak; Carol L Beglan; B K Seidleck; Laura D Hirshbein; C J Blaschak; George R. Uhl; Christopher K Surratt
Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
Molecular pharmacology 1997;52(6):983-92.
1994: Christopher K Surratt; P S Johnson; A Moriwaki; B K Seidleck; C J Blaschak; Jia Bei Wang; George R. Uhl
-mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity.
The Journal of biological chemistry 1994;269(32):20548-53.
1993: Christopher K Surratt; Jia Bei Wang; S Yuhasz; Mario Amzel; H Moo Kwon; J S Handler; George R. Uhl
Sodium- and chloride-dependent transporters in brain, kidney, and gut: lessons from complementary DNA cloning and structure-function studies.
Current opinion in nephrology and hypertension 1993;2(5):744-60.
1993: Christopher K Surratt; A M Persico; X D Yang; S R Edgar; G S Bird; A L Hawkins; Constance A Griffin; X Li; Ethylin Jabs; George R. Uhl
A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifies TaqI RFLPs.
FEBS letters 1993;318(3):325-30.
1993: A M Persico; Charles W Schindler; M T Brannock; A M Gonzalez; Christopher K Surratt; George R. Uhl
Dopaminergic gene expression during amphetamine withdrawal.
Neuroreport 1993;4(1):41-4.